



23rd International Colloquium on Lung and Airway Fibrosis
 10-14 October 2026 | Doltone House, Darling Island Wharf | Sydney, Australia

SCIENTIFIC PROGRAM

Saturday 10 October 2026

1400 – 1715	Welcome session	Tamera Corte
1400 – 1500	Afternoon tea and registration	
1500 – 1510	Welcome to ICLAF (10)	Tamera Corte
1510 – 1530	Welcome to Country (20)	Binowee Bayles
1530 – 1535	Consumer perspective (5)	Brendan Pickles
1535 – 1540	Introduction to Plenary Session (5)	Nicole Goh
1540 – 1620	Plenary: The silicosis epidemic and the Australian response (25+15)	Ryan Hoy
1620 – 1625	Introduction to Geoff Laurent Lecture (5)	Gisli Jenkins
1625 – 1705	Geoff Laurent Lecture: Fibrosis of the future (25+15)	Patricia Sime
1705 – 1715	Wrap up and the week ahead (10)	Tamera Corte
1715 – 2000	Welcome reception – Doltone House, Darling Island Wharf	

Sunday 11 October 2026

		Daniel Chambers
Session 1	Redefining interstitial lung disease to drive progress	
815 – 1000	Chairs: Margaret Wilsher and Wim Wuyts	
815 – 820	Introduction (5)	Chairs
820 – 840	Beyond aetiology and morphology for the future (20)	Chris Ryerson
840 – 900	Understanding BIP - is this a new entity? (20)	Martin Kolb
900 – 915	Discussion (15)	All
915 – 935	Novel approaches to modelling lung function (15+5)	Margaret Salisbury
935 – 955	Leveraging registries in the modern era (15+5)	Jeremy Wrobel
955 – 1005	Abstract 1: The end of rarity: The evolving burden of interstitial lung diseases in England (7+3)	Vidya Navaratnam
1005 – 1030	Morning break (25)	
Session 2	Understanding ageing to crack pulmonary fibrosis	
1030 – 1200	Chairs: Jane Bourke and Dean Sheppard	
1030 – 1035	Introduction (5)	Chairs
1035 – 1100	Concepts of biological age (20+5)	Ana Mora
1100 – 1125	Anti-ageing strategies in pulmonary fibrosis (20+5)	Louise Hecker
1125 – 1135	Clonal haematopoiesis (7+3)	Isis Fernandez
1135 – 1145	Abstract 2: Targeting age-dependent pathological dysfunction in IPF: Repurposed NRF2 activator suppressed fibrotic programs in IPF tissue and novel inhaled formulation strategy (7+3)	Kosuke Kato
1145 – 1155	Abstract 3: Lineage-specific senescence signatures reveal distinct macrophage lineages and transitional AT2 states in idiopathic pulmonary fibrosis lung explant tissue (7+3)	Peter Allen
1200 – 1300	Lunch break (60)	



Session 3
1300 – 1530

Poster discussion series

1500 – 1530 **Afternoon break concurrent with poster discussion series (30)**

Session 4
1530 – 1740

Emerging genetic paradigms in pulmonary fibrosis
Chairs: John S. Kim and Maria Molina Molina

1530 – 1535	Introduction(5)	Chairs
1535 – 1600	Familial pulmonary fibrosis – Global insights (20+5)	Raphael Borie
1600 – 1620	Rare variants – Moving the field forward (15+5)	Joanne Dickinson
1620 – 1640	Global approach to understanding common variants in pulmonary fibrosis (15+5)	Anna Peljto
1640 – 1650	Abstract 4: Correlation is not concordance: Platform-dependent telomere length classification in fibrotic ILD (7+3)	Erica Farrand
1650 – 1700	Abstract 5: Clinical characteristics, next-generation sequencing results and outcomes of familial pulmonary fibrosis: Data from the Precise-PF prospective cohort study of familial pulmonary fibrosis (7+3)	Aoife Carolan
1700 – 1710	Abstract 6: Spatial mapping of telomere attrition in idiopathic pulmonary fibrosis reveals niche-driven heterogeneity independent of peripheral blood telomere length (7+3)	Lai-Ying Zhang
1710 – 1720	Abstract 7: Telomere length and diagnostic pathways to incident fibrotic interstitial lung disease in UK biobank (7+3)	Graham Lough
1720 – 1740	Clinical genetics in pulmonary fibrosis (15+5)	Christine Garcia
1800 – 2130	Casual dinner – Manly Pavilion, Manly	

Monday 12 October 2026

Nicole Goh

Session 5
815 – 935

Taking advanced imaging the next step
Chairs: Grace Hyun J. Kim and John McDonough

815 – 820	Introduction (5)	Chairs
820 – 845	The future of imaging AI in interstitial lung disease (20+5)	Stephen Humphries
845 – 905	PET scans to improve understanding of interstitial lung disease (15+5)	Sydney Montes
905 – 915	Abstract 8: Mass-based CT texture quantification is associated with mortality in patients with systemic sclerosis interstitial lung disease (7+3)	Na'ama Avitzur
915 – 925	Abstract 9: A composite deep-learning algorithm staging model for outcome prediction in idiopathic pulmonary fibrosis scores (7+3)	John Mackintosh
925 – 935	Abstract 10: Validation of thoracic ultrasound criteria for screening rheumatoid arthritis-associated interstitial lung disease: A multicentre study (7+3)	Maria Otaola

935 – 1000 **Morning break (25)**

Session 6
1000 – 1145

Understanding and targeting cellular cross-talk in the fibrotic niche
Chairs: Zea Borok and Dan Chambers

1000 – 1005	Introduction (5)	Chairs
1005 – 1025	Link between biology and structure in pulmonary fibrosis (15+5)	Tillie Hackett
1025 – 1045	Neural regulation of fibrosis (15+5)	Erica Herzog



1045 – 1055	Abstract 11: Claudin-1 upregulation and ectopic expression mark a pathogenic alveolar epithelial program in early disease in idiopathic pulmonary fibrosis (7+3)	Emanuela Cortesi
1055 – 1105	Abstract 12: Granulomatous fibrosis in silicosis is characterized by diverse profibrotic macrophage states uncoupled from epithelial niches (7+3)	Nebal Abu Hussein
1105 – 1115	Abstract 13: MCEMP1-SPP1 axis orchestrates myeloid–fibrotic crosstalk in pulmonary fibrosis (7+3)	Jose Herazo-Maya
1115 – 1125	Abstract 14: BCL9 inhibition promotes fibroblast lipogenesis by regulating macrophage–fibroblast interactions to attenuate pulmonary fibrosis (7+3)	Wenjie Wang
1125 – 1145	Panel discussion: Invited speakers and chairs (20)	
Session 7	Dan Rose Session – Improving quality of life for pulmonary fibrosis patients	
1145 – 1320	Chairs: Anne-Marie Russell and Stefan Stanel	
1145 – 1150	Introduction (5)	Chairs
1150 – 1200	Integrating consumer perspectives in your research (7+3)	Anne Holland
1200 – 1205	Introduction to Dan Rose Lecture (5)	Anne-Marie Russell
1205 – 1235	Dan Rose Lecture: Measuring life with pulmonary fibrosis: The other side of the meter stick (25+5)	Jeff Swigris
1235 – 1320	Round table: Consumers and the future of pulmonary fibrosis research Mark Brooke, Anne Holland, Marcia Hooper, Jeff Swigris (45)	Tania Hyde
1320	Lunch and social activities	
1800	Optional gathering	

Tuesday 13 October 2026

Steve Mutsaers

Session 8	Emerging mechanisms and therapeutic targets in pulmonary fibrosis	
815 – 1000	Chairs: Alastair Stewart and Amanda Tatler	
815 – 820	Introduction (5)	Chairs
820 – 840	Extending beyond characterization of fibroblast subtypes (15+5)	Dianhua Jiang
840 – 900	Pro-fibrotic epithelial phenotypes (15+5)	Rachel Zemans
900 – 920	Surfactant protein C and fibrosis (15+5)	Jenny Dickens
920 – 940	The role of the endothelium and vasculature in pulmonary fibrosis (15+5)	Sukhwinder Sohal
940 – 950	Abstract 15: PNA-33, a targeted miR-33 inhibitor, reprograms macrophages to orchestrate lipid metabolism and ferroptosis in the lung, accelerating epithelial regeneration and reversing pulmonary fibrosis (7+3)	Farida Ahangari
950 – 1000	Abstract 16: An MMP7-dependent CTGF fragment orchestrates a fibrotic airway niche in idiopathic pulmonary fibrosis and is neutralized by a novel epitope-binding antibody (7+3)	Heiko Olbrich
1000 – 1030	Morning break (30)	
Session 9	We are what we breathe: The environmental impact on fibrosis	
1030 – 1155	Chairs: Juan Enghelmayer and Lauren Troy	
1030 – 1035	Introduction (5)	Chairs
1035 – 1100	Incidental lifetime exposures: what do we tell patients	Kerri Johansson



	and governments? (20+5)	
1100 – 1125	How does our environment impact pulmonary fibrosis on a cellular level (20+5)	Jennifer Larson-Casey
1125 – 1135	Wildfires and pulmonary fibrosis (7+3)	Paris Papagianis
1135 – 1145	Abstract 17: Long-term PM2.5 exposure is associated with circulating extracellular matrix remodelling biomarkers in pulmonary fibrosis: Results from the PROFILE cohort (7+3)	Athina Trachalaki
1145 – 1155	Abstract 18: Ambient air pollution, climate, land use, and small area-incidence of interstitial lung disease: A bi-national semi-ecological study (7+3)	Cheng Zhao
1155 – 1255	Lunch break (60)	
Session 10	Andy Tager Session	
1255 – 1350	Chair: Tim Blackwell and Marilyn Glassberg	
1255 – 1300	Introduction to Andy Tager Lecture (5)	Chairs
1300 – 1325	Andy Tager Lecture: Short telomere syndrome (25)	Paul Wolters
1325 – 1335	Functional insights into TERT variants (10)	Chris Reilly
1335 – 1350	Discussion (15)	All
Session 11	Therapeutic advances in pulmonary fibrosis	
1350 – 1545	Chairs: Joyce Lee and Ganesh Raghu	
1350 – 1355	Introduction (5)	Chairs
1355 – 1415	Beyond bleomycin: Building better models for pulmonary fibrosis (15+5)	Janette Burgess
1415 – 1440	New therapies on the horizon (20+5)	Toby Maher
1440 – 1500	Addressing cough in interstitial lung disease (15+5)	Surinder Birring
1500 – 1525	Treating pulmonary hypertension in interstitial lung disease in the current era (20+5)	Laura Price
1525 – 1535	Abstract 19: TETON Phase 3 clinical trials of inhaled Treprostinil for the treatment of idiopathic pulmonary fibrosis: Combined efficacy and safety results for TETON-1 and TETON-2 (7+3)	Steven Nathan
1535 – 1545	Abstract 20: Telomerase mRNA therapy rescues alveolar telomere attrition and improves lung function in pulmonary fibrosis (7+3)	John Ramunas
1545 – 1615	Afternoon break (30)	
Session 12	Immune mediated mechanisms of lung fibrosis	
1615 – 1740	Chairs: Mallar Bhattacharya and Matthew Parker	
1615 – 1620	Introduction (5)	Chairs
1620 – 1640	What can we learn from the vasculitis/IPF overlap? (15+5)	Bruno Crestani
1640 – 1700	Understanding disease pathways in scleroderma interstitial lung disease (15+5)	Mandana Nikpour
1700 – 1720	IPAF: Have we moved on? (15+5)	Mary Streck
1720 – 1730	Abstract 21: Human B cell receptor repertoire analysis reveals unique clonal differences and IGHV gene use in patients with idiopathic pulmonary fibrosis (7+3)	Cecilia Prêle
1730 – 1740	Abstract 22: Myeloid reprogramming links viral hyper-responsiveness and impaired immunological memory to exacerbation susceptibility in idiopathic pulmonary fibrosis (7+3)	Laurence Pearmain
1900 – late	ICLAF colloquium dinner - Sydney Town Hall	



Wednesday 14 October 2026

Cecilia Prêle

Session 13	Opening the flood gates: Interstitial lung abnormalities (ILAs)	
820 – 1000	Chairs: Laura Fabbri and Alan Teoh	
820 – 825	Introduction (5)	Chairs
825 – 845	Redefining ILA and early ILD - beyond the guidelines (15+5)	Anna Podolanczuk
845 – 905	Mechanisms for progression from ILA to ILD (15+5)	Jonathan Rose
905 – 920	Are we ready for screening in prime-time? (10+5)	Coline van Moorsel
920 – 940	What treatments are in the pipeline for ILA and early ILD? (15+5)	Gary 'Matt' Hunninghake
940 – 950	Abstract 23: Proteomic biomarkers of lung injury on chest computed tomography and future quantitative interstitial lung abnormalities (7+3)	Kavitha Selvan
950 – 1000	Abstract 24: Differences in physiologic responses to exercise between men and women with interstitial lung abnormalities (7+3)	Deborah Assayag
1000 – 1030	Morning break (30)	
Session 14	More than biomarkers: Moving OMICS to the clinic	
1030 – 1200	Chairs: Melanie Koenigshoff and Argyris Tzouvelekis	
1030 – 1035	Introduction (5)	Chairs
1035 – 1045	Abstract 25: Serum biomarkers associated with progression in non-IPF fibrotic interstitial lung disease: Primary endpoint analysis of the INJUSTIS study (7+3)	Iain Stewart
1045 – 1105	Using single cell sequencing for drug targeting in interstitial lung Disease (15+5)	Ivan Rosas
1105 – 1130	Using spatial transcriptomics to understand pulmonary fibrosis pathogenesis (20+5)	Nicholas Banovich
1130 – 1140	Abstract 26: Effects of nerandomilast on peripheral blood protein biomarkers in patients with idiopathic pulmonary fibrosis (7+3)	Justin Oldham
1140 – 1150	Abstract 27: Genotype-stratified spatial transcriptomics profiling reveals distinct niche remodelling programs in idiopathic pulmonary fibrosis (7+3)	Kevin Bin Liu
1150 – 1155	Closing remarks from patient representative (5)	Deborah Murray
1155 – 1200	Meeting close (5)	Tamera Corte
1200 – 1300	Lunch and departures	